NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its third quarter revenues fell 2 percent mostly due to a 5 percent dip in revenues from its non-invasive heart transplant rejection test AlloMap.

For the three months ended Sept. 30, the firm reported total revenues of $12.2 million, down from $12.5 million in Q3 2016, but beating the average Wall Street estimate for revenues of $12.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.